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Abstract 
This protocol describes an efficient novel method for cultivating kidney cancer organoids, 
derived directly from human clear cell renal cell carcinomas (ccRCC) or sorted cancer stem 
cells. The organoids recapitulate tumor-specific characteristics and display inter-tumor 
heterogeneity. Here we explain how to establish the organoid cultures, maintain them in 
defined, serum-free medium and use them for patient-specific drug testing. Within 10-14 
days, a patient-derived organoid culture is established and can be serially passaged. 
Compared to other protocols focusing on organoid cultures derived from pediatric kidney 
malignancies or healthy kidneys, the protocol described here is optimized for adult ccRCC 
organoid cultures. Organoids established using this protocol can be used to further 
investigate tumor biology in a complex 3D in vitro system, complement current preclinical 
model-based drug studies, and advance the development of personalized therapy design.  
 
INTRODUCTION 
Kidney cancer is the twelfth most common malignancy in the western world and clear cell 
renal cell carcinoma (ccRCC) is its most common form1. Even though significant advances 
have been made in the treatment of ccRCC, including receptor tyrosine kinase inhibitors and 
monoclonal antibodies targeting VEGF-dependent angiogenesis, and more recently immune 
checkpoint inhibitions, the lack of suitable preclinical models has certainly impeded kidney 
cancer research both regarding the development of novel drugs as well as the stratification of 
suitable predictive biomarkers2,3. Therefore, improving the long-term prognosis of ccRCC will 
require novel models that pave the way to personalized medicine, which offers treatments 
that are specific to the biology of each tumor. Organoid cultures have increasingly been 
shown to recapitulate a tumor in vitro4. We have developed and characterized a novel ccRCC 
organoid culture system, which could be used to test the patient-specific response to 
treatment strategies in vitro5. In this protocol, we provide further detailed instructions on how 
to establish and maintain these culture systems and evaluate them for your individual 
research needs. 
 
Comparison with other methods 
Organoid culture conditions, described here, were adapted from those previously described, 
but were tailored to the specific needs of kidney cancer cells6,7. We optimized different 
conditions, enabling us to achieve long-term growth of primary ccRCC tissue with high 
efficiency. The composition of the medium is summarized in Table 2. We have shown that 
organoids exhibit kidney-specific epithelial differentiation, while retaining cancer stem cell 
populations. Organoids resemble proximal tubule structures – the potential cell of origin of 
ccRCC – and recapitulate typical characteristics of ccRCC, including glycogen deposits and 
lipid droplets5. 
An earlier described kidney cancer organoid culture has established healthy kidney 
organoids and matched cancer organoid cultures. However, cancer organoid formation 
efficiency was much lower and organoids could only be maintained for few passages8. Other 
recently published organoid cultures have focused on pediatric cancers, including Wilm’s 
tumors, malignant rhabdoid tumors, renal cell carcinomas, and congenital mesoblastic 
nephromas9,10. 
  
Applicat ions and l imitat ions of the protocol 
Since organoids closely recapitulate several properties of the original tumor and since they 
are scalable for high-throughput drug screens, they present excellent in vitro systems that 
connect clinical trials with cancer genetics, complement current preclinical model-based drug 
studies and advance the development of personalized therapy design. This has been 
successfully demonstrated in colorectal cancer organoids as well as in our study on kidney 
cancer organoids5,11. 
Organoid technology can be combined with genome editing technologies to better 
understand specific disease mechanisms. The first CRISPR-generated genetic model of 
pluripotent stem cell-derived renal organoids modeled polycystic kidney disease12. Genome 
editing to model kidney cancer has not been done. However, in intestinal organoids, 
CRISPR-mediated gene modification of the most commonly mutated genes resulted in niche 
factor independence and carcinoma formation after xenotransplanation13. Moreover, 3D cell 
culture systems can be used in large CRISPR screens to determine growth-specific 
vulnerabilities that may lead to the development of novel therapeutic strategies14.  
In our work, we focused on the determination of a cancer stem cell population and its 
implications for patient-specific therapy response in different patient-derived cancer 
systems5. Therefore our focus was to optimize growth conditions for tumor organoids. Growth 
of organoids derived from adjacent kidney tissue was less efficient in the developed tumor 
organoid medium. We conclude that the culture conditions would have to be adapted to the 
needs of healthy kidney tissue to derive a matched healthy kidney organoid. 
Experimental Design 
Overview of the procedure 
In our detailed protocol, we describe the establishment and cultivation of human renal 
carcinoma-derived organoids. The main procedure outlines the mechanical preparation and 
enzymatic digestion of the tumor tissues as well as the subsequent cell plating and organoid 
passaging (Steps 1-3). Cells are cultivated in Matrigel and cultured in defined medium, which 
is exchanged every 2-3 days. Cell rounding and organoid formation can be observed after 2-
3 days.  We also describe protocols for cryopreservation of kidney cancer organoids to build 
up personal biobanks (Step 4A) and for organoid preparation for immunocytochemistry, 
whole-mount confocal microscopy, and transmission electron microscopy (Steps 4B-D) as 
well as for harvesting organoids for protein analyses and RNA extraction (Step 4E). 
Additionally, we describe the setup of a multi-well drug assay to systematically examine the 
effects of large- and small-molecule inhibitors on organoid viability (Step 4F). 
Culture medium 
In this protocol, kidney cancer organoid cultures are grown in defined medium – its 
composition is summarized in Table 2. Unlike other organoid cultures, kidney cancer 
organoids exhibited no requirement for R-Spondin 1, since endogenous autocrine 
mechanisms to upregulate Wnt signaling were found5. Kidney cancer organoids showed 
strong dependence on EGFR and FGF. However, several other growth factors implicated in 
kidney development resulted in no benefit to organoid formation. We still expect that further 
optimizing the culture medium to obtain healthy kidney organoids is possible. For high 
efficiency of culture establishment and successful long-term maintenance, we suggest using 
appropriately stored mixtures of growth factors and chemical compounds, and using freshly 




• Agarose (Invitrogen, cat. no. 15510-027) 
• Amphotericin B (Biomol, cat. no. A2230) 
• B-27 Supplement (Life Technologies, cat. no. 17504044) 
• Blood and Cell Culture DNA Kit (Qiagen, cat. no. 13323) 
• Bovine Serum Albumin (BSA) (Sigma-Aldrich, cat. no. A3733) 
• CD45 MicroBeads, Human (Miltenyi Biotec, cat. no. 130-045-801) 
• Cell Recovery Solution (Corning, cat. no. 354253) 
• CellTiter Glo Cell Viability Assay Substrate and Buffer (Promega, cat. no. G7572) 
• Chloroform (Roth, cat. no. 3313.2) 
• Collagenase P (Roche, cat. no. 11213865001) 
• DAPI (Thermo Fisher, cat. no. D1306) 
• DMEM/F-12, GlutaMAX™ supplement (Life Technologies, cat. no. 10565018) 
• Donkey serum (Bio-Rad, cat. no. C06SB) 
• EDTA (Roth, cat. no. 8043.2) 
• EtOH 100% (Roth, cat. no. 9065.2) 
• Entellan new (Merck, cat. no. 107961) 
• Eosin (Merck, cat. no. 1.15935.0100) 
• Fetal Bovine Serum (FBS) (Life Technologies, cat. no. 10270-106) 
• Formaldehyde 35% (Roth, cat. no. 4980.2) 
• Glutaraldehyde (Roth, cat. no. 4995.2) 
• HCl (Merck, cat. no. 1.09057.1000) 
• Hematoxylin (Fluka AG, cat. no. 51260)  
• Heparin (Sigma-Aldrich, cat. no. H3194) 
• Human EGF (Peprotech, cat. no. AF-100-15) 
• Human FGFb (basic) (Thermo Fisher, cat. no. 68-8785-82) 
• Immumount® (Thermo Scientific, cat. no. 9990402) 
• KCl (Roth, cat. no. 6781.1) 
• KH2PO4 (Roth, cat. no. 3904) 
• L-Glutamine (Biochrom, cat. no. K0283) 
• Lead (II) Citrate (Sigma-Aldrich, cat. no. C6522) 
• Matrigel (Corning, cat. no. 354230) 
• MEM with Earle’s Salts with 2.2 g/l NaHCO3, without L-glutamine (Biochrom, cat. no. 
F0325) 
• Milli-Q water 
• Na2HPO4 x 2H2O (Roth, cat. No. 4984.1) 
• N-acetylcysteine (Sigma-Aldrich, cat. no. A9165) 
• NaCl (Merck, cat. no. 1.06404.1000) 
• NaOH (Merck, cat. no. 1.09137.1000) 
• Non-Essential Amino Acids (NEAA) (Life Technologies, cat. no. 11140-050) 
• Osmium Tetroxide (Sigma-Aldrich, cat. no. 75632) 
• Paraplast (Surgipath, cat no. 39601006) 
• Penicillin-Streptomycin (Life Technologies, cat. no. 15140-122) 
• Polyacryl Carrier (Molecular Research Center, cat. no. PC 152) 
• PolyBed 812 resin (Polysciences Inc., cat. no. 08792-1) 
• Recovery Cell Culture Freezing Medium (Thermo Fisher, cat. no. 12648010) 
• Toluol (Roth, cat. no. 7115.2) 
• Tris (Sigma Life Science, cat. no. T1503) 
• TRIzol (Ambion, cat. no. 15596018) 
• Trypan Blue (Sigma-Aldrich, cat. no. 93590) 
• TrypLE Select (Life Technologies, cat. no. 12563-011) 
• Tween 20 (SERVA, cat. no. 9005-64-5) 
• Agarose Low Melt (Roth, cat. no. 6351.1) 
• Uranyl Acetate (Polysciences Inc., cat. no. 21447-25) 






• Biotinylated Lotus Tetragonolobus Lectin (LTL) (Vector Laboratories, cat. no. B-1325) 
• Anti-Carbonic Anhydrase IX (CA9), Rabbit (abcam, cat. no. ab128883) 
• Anti-E-Cadherin (ECAD), Mouse (BD Biosciences, cat. no. 610181) 
Secondary antibodies/conjugates 
• Anti-Mouse-Cy3, Donkey (Jackson, cat no. 715-165-151) 
• Anti-Rabbit-Alexa-488, Donkey (Jackson, cat. no. 711-546-152) 
• Streptavidin-Alexa-647 (Thermo Scientific, cat. no. S21374) 
 
 
TABLE 1 | Dilutions of primary and secondary antibodies/conjugates used for 
characterization of organoids. 
















• Analytical Balance Scale R200D (Sartorius Research) 
• BBD6220 CO2 Incubator (Thermo Scientific) 
• Cell Culture Multiwell Plate, 48 Well, clear, Advanced TC, sterile, with lid (CellStar, 
cat. no. 677 980) 
• Cell strainer, 40 µm, Nylon (Falcon, cat. no. 352340) 
• Cell strainer, 70 µm, Nylon (Falcon, cat. no. 352350) 
• Confocal Microscope LSM 710 NLO (Zeiss) 
• Cover Glass, 24x60 (Roth, cat. no. H878) 
• Electron Microscope EM 910 (Zeiss) 
• Eppendorf 5424R Centrifuge (Eppendorf) 
• Freezer (Sanyo) 
• Hemocytometer (Neubauer) 
• Horizontal Shaker Duomax 1030 (Heidolph) 
• Injekt Disposable Syringe, 20 ml (BRAUN, cat. no. 4606205V) 
• Internal Threaded Polypropylene Cryogenic Vial, Self-Standing with Round Bottom, 2 
ml (Corning, cat. no. 430488) 
• Inverted Microscope ID03 (Zeiss) 
• Leica DMI 6000 B Microscope (Leica) 
• Liquid Nitrogen BIOSAFE-CONTROL ß (Cryotherm) 
• Luminometer LB90S (Berthold Technologies) 
• MACS MultiStand (Miltenyi Biotec, cat. no. 130-042-303) 
• Magnetic Stirrer with Hot Plate (IKAMAG) 
• Microcentrifuge DW-41BR-230 (Qualitron) 
• Microtome HM355S (Microm) 
• Microwave (Sharp) 
• Milli-Q Water Purification System (Merck) 
• Mini metal base molds (Leica Biosystems) 
• MS columns (Miltenyi Biotec, cat. no. 130-042-201) 
• Multifuge 4KR (Thermo Scientific) 
• OctoMACS Separator (Miltenyi Biotec, cat. no. 130-042-109) 
• Orbital Shaker Unimax 1010 with Incubator 1000 (Heidolph) 
• Rotilabo-embedding cassettes, white (Roth, cat. no. K113.1)  
• Paraffin Embedding Station EC 350 (Microm) 
• Paraffin Oven (Binder) 
• Pre-separation filters, 30 µm (Miltenyi Biotec, cat. no. 130-041-407) 
• Refrigerator (Liebherr) 
• Round Bottom Polystyrene Test Tube, with Snap Cap, 5 ml (Falcon, cat. no. 352058) 
• µ-Slide 8 Well Glass Bottom (ibidi, cat. no. 80827) 
• Slide Microscope Axio Scope.A1 (Zeiss) 
• Slide Warmer SW85 (Adamas Instrumenten BV) 
• Sterile Workbench Safe 2020 (Thermo Scientific) 
• SuperFrost Plus Adhesion slides (Thermo Scientific, cat. no. J1800AMNZ) 
• Surgical Disposable Scalpels (BRAUN, cat. no. 5518075) 
• Syringe Filter, FP 30\0.2 CA-S (Whatman, cat. no. 10462206) 
• TC Dish 100, Standard (Sarstedt, cat no. 83.3902) 
• Thermomixer 5436 Heating Block (Eppendorf) 
• Tube Roller (Star Lab Smart Instruments) 
• Water Bath 1003 (GFL) 




• iTEM software (Emsis GmbH) 
• LAS X (Leica) 
• Zen 2 Black/Blue Edition (Zeiss) 
 
REAGENT SETUP 
CRITICAL All non-sterile reagents used for cell culture conditions must be filtered through a 
disposable 0.2 µm filter. 
Heparin Dissolve 5 mg in 1 ml of Milli-Q water, aliquot, and store at -20°C until the 
expiration date. 
Human EGF Dissolve 100 µg in 50 µl of PBS 1x, mix with 50 µl of 0.1% BSA in PBS (w/v) 
to 1 mg/ml, aliquot, and store at -80°C until the expiration date. 
Human FGFb (basic) Dissolve 100 µg in 625 µl of PBS 1x, mix with 625 µl of 0.1% BSA 
in PBS (w/v) to 80 µg/ml, and store at -80°C until the expiration date. 
MACS buffer 2.5 g of BSA (0.5% w/v), 0.29224 g of EDTA (2 mM), ad 500 ml of PBS 1x, 
store at 4°C for maximum 6 months.  
Medium for human tumor-derived organoids Final concentrations of medium 
components are listed in the table 2. To prepare 50 ml of the medium, to 48.2 ml of DMEM/F-
12 medium add 1 ml of 50x B-27 Supplement, 1 µl of 1 mg/ml EGF, 12.5 µl of 80 µg/ml 
FGFb, 40 ul of 5 mg/ml Heparin, 500 µl of 100x Penicillin-Streptomycin, and 250 µl of 25 
mg/ml Amphotericin B. 
CRITICAL The medium should be stored at 4°C for a maximum of one week. 
Phosphate buffer (0.1 M) Solution A: Dissolve 2.72 g of KH2PO4 in 100 ml of Millie-Q 
water (0.2M). Solution B: Dissolve 8.9 g of Na2HPO4 x 2H2O in 250 ml of Millie-Q water 
(0,2M). Add 18.2 ml of Solution A to 81.8 ml of Solution B, and adjust the pH to 7.4. Ad 200 
ml of Milli-Q water. 
Phosphate Buffered Saline (PBS 1x) 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4 x 
2H2O, 0.24 g of KH2PO4, ad 1000 ml of Milli-Q water. 
PBS-T 1 ml of Tween 20 (0.1% v/v), ad 1000 ml of PBS 1x. 
Primary cel l  medium To prepare 50 ml of medium, to 43.25 ml of MEM add 5 ml of FBS, 
500 µl of 200 mM L-Glutamine, 500 µl of 100x NEAA, 500 µl of 100x Penicillin-Streptomycin, 
and 250 µl of 25 mg/ml Amphotericin B. Store at 4°C for maximum one month. 
RBC erythrocyte lysis buffer 4.0118 g of ammonium chloride, 0.5 g of potassium 
bicarbonate, 0.0146 g of EDTA, ad 1000 ml of Milli-Q water, adjust pH to 7.4, store at 4°C for 
maximum 6 months.  
DNase I Dilute 5 mg or 10.000 U in 1 ml sterile water. Store at -20ºC for a year. 
 
TABLE 2 | Final concentrations of medium components for organoid culture. 
Medium Component Human tumor-derived organoids 
B-27 supplement 1x 
Human EGF 20 ng/ml 
Human FGFb (basic) 20 ng/ml 
Heparin 4 µg/ml 
Penicillin-Streptomycin 1x 
Amphotericin B 125 µg/ml 
PROCEDURE 
Establ ishing and cultur ing renal organoid cultures 
1| Pre-warm tissue culture plates overnight at 37°C and thaw Matrigel on ice several 
hours or overnight before use. 
2| Establ ishing organoids from human renal cel l  carcinoma (RCC) biopsies
 TIMING up to 14 d 
i. Wash RCC tissue specimens, directly obtained from surgery, and remove fatty and 
necrotic tissue. 
ii. Use a scalpel to mince the tissue biopsy into small pieces of < 1 mm3 size. 
iii. Take up the pieces in 10 ml of PBS and transfer them to a 50 ml falcon tube. 
Centrifuge at 300 x g for 5 min at 4°C, and weigh the pellet after aspirating the 
supernatant. 
CRITICAL STEP: Weigh the empty Falcon tube before transferring the tissue to 
calculate the weight of the sample. 
iv. Prepare one ml of 2 mg/ml Collagenase P solution per 50 mg of tissue and digest the 
tissue at 37°C for approx. 30 min, rocking gently. 
? TROUBLESHOOTING 
v. Wash with 25 ml PBS and centrifuge at 300 x g for 5 min at 4°C. 
vi. Resuspend the sample in 5 ml of PBS, and filter the cell suspension through a 70 µm 
followed by a 40 µm cell strainer. Wash the filters 3x with PBS. 
vii. Centrifuge the eluate at 300 x g for 5 min at 4°C, and wash the cell pellet with PBS.  
viii. Incubate in 5 ml of RBC erythrocyte lysis buffer for 5 min at RT. 
ix. After washing in PBS, count the cells using a hemocytometer and resuspend in 80 µl 
MACS buffer per 1 x 107 cells. Add 20 µl of anti-CD45 Microbeads per 80 µl of cell 
suspension and incubate for 15 min at 4°C.  
Optional: Add DNase I at a final concentration of 200 U/ml to the MACS buffer if you 
experience excessive cell clumping. 
x. Wash the cells in 2 ml of MACS buffer per 1 x 107 cells before resuspending the pellet 
in 500 µl of MACS buffer per 1 x 108 cells. 
xi. After the magnetic separation of CD45+ white blood cells (WBC) using a 30 µm pre-
separation filter and a MACS buffer equilibrated MS column, collect the CD45- cells in 
the flow-through, and wash the column three times with 500 µl of MACS buffer. 
? TROUBLESHOOTING 
xii. Centrifuge the CD45- cell suspension at 300 x g for 5 min at 4°C, resuspend in PBS 
and count the alive (unstained) cells by mixing 10 µl of 0.4% (w/v) Trypan Blue 
solution with 10 µl cell solution. 
xiii. Resuspend 1.5 x 104 cells per well in pre-chilled growth medium and dilute with 
Matrigel to a final concentration of 75% Matrigel. Plate 25 µl cell-Matrigel drops in the 
middle of the well of a pre-heated 48-well plate. 
CRITICAL STEP: Work quickly and constantly on ice to prevent Matrigel from 
polymerizing before plating. Resuspend cells in pre-chilled growth medium before 
adding the Matrigel. 
CRITICAL STEP: Do not dilute the Matrigel beyond 75% to guarantee sufficient 
stiffness, and to prevent Matrigel lens rupture during cultivation. 
xiv. Place the tissue culture plate upside down in the CO2 incubator, while the Matrigel 
containing the cells solidifies for 15 min at 37°C. 
CRITICAL STEP: Invert the plates to prevent cell descent and adherence to the 
well bottom. 
xv. Gently add 250 µl of pre-warmed organoid growth medium into each well, and place 
the plate into a CO2 incubator (5% CO2, 37°C). 
CRITICAL STEP: Medium, which is not pre-warmed, may cause Matrigel lens 
rupture, and decrease organoid formation efficiency. 
xvi. Refresh the medium every 2-3 days. Check organoid growth daily using a brightfield 
microscope. After 3-4 days, small organoids should be visible. 
xvii. Passage the organoids when they reach a diameter of 300-500 µm (usually after 10-
14 days). 
3| Passaging of organoids  TIMING variable 
i. Using a 1 ml pipette tip, release organoids from Matrigel lenses by pipetting up and 
down several times and transfer them to a 15 ml falcon tube coated with 1% BSA in 
PBS (w/v). 
? TROUBLESHOOTING 
ii. Wash the wells with 1 ml of PBS to obtain all cells, and add them to the falcon tube. 
CRITICAL STEP: Harvest the organoids in at least 5 ml of total volume to allow 
better perturbation in the following step. 
? TROUBLESHOOTING 
iii. Pipet thoroughly using a 100 µl tip on a 5 ml serological pipet to fully release the 
organoids from the Matrigel. 
CRITICAL STEP: By using a 100 µl tip on a 5 ml serological pipet, you can 
simultaneously perturb a large volume of the organoids, and create strong enough 
shear forces to more efficiently release the organoids from the Matrigel. 
iv. To eliminate dead cells, cells not within the growing organoids or without organoid 
formation potential, filter the cell suspension through a 70 µm cell strainer. 
CRITICAL STEP: We recommend this for the first 1-2 passages. It is however not 
necessary once organoid cultures are well established. 
v. Wash the strainer with 5 ml of growth medium and invert the cell strainer onto a 10 
cm2 dish. 
vi. Wash the retained organoids from the membrane with 10 ml of growth medium, and 
collect the organoids in a 15 ml falcon tube. 
vii. Centrifuge at 300 x g for 5 min at 4°C, and aspirate the supernatant and Matrigel 
above the pellet. At this point, the organoids can be passaged or further processed 
for e.g.: 
a. RNA isolation with TRIzol, 
b. gDNA isolation using the Blood and Cell Culture DNA Kit, 
c. Protein Isolation using the Cell Recovery Solution. 
viii. Resuspend the organoids in 300-500 µl of TrypLE Select cell dissociation enzyme 
solution and incubate for 5-15 min at RT with frequent perturbation by pipetting. 
Check organoid dispersion under the bright-field microscope. 
CRITICAL STEP: Organoid dissociation can easily be monitored by holding the 
falcon tube at an angle in the light path of a bright-field microscope, thereby 
eliminating the need for a hemocytometer for this step.  
CRITICAL STEP: If the organoids have not yet reached 300-500 µm in diameter, 
but their density is high, we recommend releasing the organoids from the Matrigel, as 
described in step i-iv, and reseeding at lower densities. 
ix. When the organoids are dispersed to smaller cell clusters, stop the digestion by 
adding 4 ml of growth medium, and centrifuge the organoids at 300 x g for 5 min at 
4°C. 
x. Resuspend the organoids in pre-chilled medium and add Matrigel to a final 
concentration of 75% Matrigel. Plate 25 µl drops in the middle of the well of a pre-
heated 48-well plate. 
CRITICAL STEP: Work quickly and constantly on ice to prevent Matrigel from 
polymerizing before plating. Resuspend cells in pre-chilled growth medium before 
adding the Matrigel. 
xi. Place the tissue culture plate upside down in the CO2 incubator, while the Matrigel 
containing the cells solidifies for 20 min at 37°C. 
CRITICAL STEP: Invert the plates to prevent cell descent and adherence to the 
well bottom. 
xii. Gently add 250 µl of pre-warmed organoid growth medium into each well, and place 
the plate into a CO2 incubator (5% CO2, 37°C). 
CRITICAL STEP: Medium, which is not pre-warmed, may cause Matrigel lens 
rupture, and decrease organoid formation efficiency. 
xiii. Refresh the medium every 2-3 days. Check organoid growth daily using a brightfield 
microscope. One day after passaging, small organoids should be visible. Generally, 
the organoids were passaged in a 1:2 dilution. 
 
Downstream Assays 
4 |   Once organoid cultures have grown to sufficient size, organoids can be cryopreserved 
(option A). Specific marker expression can be analyzed by immunofluorescence after 
organoid embedding for paraffin sectioning (option B) or whole mount imaging via confocal 
microscopy (option C). Detailed morphological characterization can be achieved by 
transmission electron microscopy (option D) and proteins can be isolated (option E). 
Organoid cultivation can be upscaled for high-throughput drug testing of inhibitory and 
nephrotoxic effects on organoid proliferation and viability (option F).   
(A)  Cryopreservation of organoids  TIMING 30 min 
 
i. Release the organoids from Matrigel and dissociate them into clusters as described in 
steps 3| i-ix. 
CRITICAL STEP: Organoid reformation and viability was greatly increased, when 
cells were cryopreserved as clusters instead of whole organoids. 
ii. Resuspend the organoid clusters in 1 ml of Recovery Cell Culture Freezing Medium 
per 2-3 wells of the dissociated organoids, and transfer to cryotubes. 
iii. Freeze the cryostocks for at least 6 hours in isopropanol containers at -80°C before 
storage in liquid nitrogen.  
PAUSE POINT: The dissociated organoids can be stored up to 30 days at -80°C. 
For long-term storage (> 1 month), transfer the cryostocks to liquid nitrogen. 
iv. When you wish to take cells back into culture, thaw the cells in a 37°C water bath. 
CRITICAL STEP: Shake the vial in the 37°C water bath until only a small piece of 
ice remains and quickly continue processing the cells to reduce cell stress. 
v. Transfer the thawed cells into a 15 ml falcon tube, and dropwise add 10 ml of pre-
warmed growth medium. 
vi. Centrifuge at 300 x g for 5 min at 4°C. 
vii. Aspirate the supernatant, and resuspend the cell pellet in 75% Matrigel. 
viii. Plate the organoids as described in steps 3| x-xiii. We recommend seeding the 
dissociated organoids in a 1:2 dilution, meaning seeding 1 cryostock of 2-3 wells in 4-
6 fresh wells. 
 
 
(B)  Embedding of organoids in agarose for paraff in sectioning 
TIMING 4-5 d 
 
i. Release the organoids from Matrigel as described in steps 3| i-iii  
ii. Centrifuge the organoids at 300 x g for 5 min at 4°C, and discard the supernatant, 
including Matrigel and dead cells.  
iii. Wash the organoids with 0.1% BSA in PBS (w/v), and centrifuge at 300 x g for 5 min 
at 4°C. 
iv. Resuspend the organoids in 7 ml of 10% NBF in PBS (v/v), and fix over night at  
4°C rocking. 
v. Wash the organoids with 0.1% BSA in PBS (w/v), resuspend in 500-1000 µl of 0.1% 
BSA in PBS (w/v), transfer to a coated 2 ml Eppendorf tube, and centrifuge at 300 x g 
for 5 min at 4°C. 
vi. Shortly place the tube in an 80°C heating block before carefully overlaying the 
organoid pellet with 400 µl of 1.5% agarose. 
? TROUBLESHOOTING 
vii. Centrifuge shortly at 300 x g at 4°C. Let the agarose solidify on ice. 
CRITICAL STEP: Place the tube in the centrifuge in the same orientation as before 
to make sure the pellet does not move from its previous position. 
viii. After the agarose has polymerized, release the agarose bead from the Eppendorf 
tube. 
CRITICAL STEP: Use a razor blade to cut off the bottom of the Eppendorf tube at 
the opposite side as the organoid pellet, and carefully push out the agarose bead.    
ix. Trim the bead around the organoid pellet, transfer it to an embedding cassette, and 
place the cassette in 70% EtOH for 24-48 h. 
PAUSE POINT: The agarose bead can remain in 70% EtOH for up to 7 days before 
dehydration.  
x. Dehydrate the organoids according to Table 3. 
xi. After embedding in paraffin, section the paraffin-embedded organoids using a 
microtome at 5 µm thickness with a water bath at a temperature of 48°C. Quickly 
transfer the sections onto glass slides to prevent the agarose from dissolving. 
xii. Place air-dried glass slides on a 60°C warming block for 15 min and in a 60°C oven 
for 60 min to fix the organoids to the glass slide before staining. 
xiii. Rehydrate the organoids before performing hematoxylin and eosin staining as well as 
immunocytochemistry. 
 
TABLE 3 | Dehydration steps of organoids in agarose beads. 
Incubation t ime Solut ion 
30 min 80% EtOH 
30 min 90% EtOH 
1h 96% EtOH 
1h 100% EtOH 
30 min 100% EtOH 
1h Toluene 
30h Toluene 
1-3h Paraffin  
Over night Paraffin  
1h  Paraffin  
 
 
(C)  Preparation of organoids for confocal microscopy  TIMING 3 d 
i. Release the organoids from Matrigel as described in steps 3| i-iii. 
ii. Resuspend the organoids in 1500 µl of 10% NBF in PBS (v/v), and transfer them to a 
2 ml coated Eppendorf tube. 
iii. Fix the organoids for 1.5h at 4°C shaking, and wash 5x with PBS-T over 2h at 4°C 
shaking. 
iv. Block with 1% BSA in PBS-T (w/v) containing 10% donkey serum for 2h at RT 
shaking. 
v. Prepare antibody dilutions in 1% BSA in PBS-T, and incubate the organoids with 
primary antibodies over night at 4°C shaking.  
vi. Wash the organoids 4x with PBS-T over 4h at 4°C shaking with centrifugation at 300 
x g for 5 min at 4°C.  
vii. Incubate with secondary antibodies and DAPI over night at 4°C shaking. 
CRITICAL STEP: Wrap the Eppendorf tubes in aluminum foil to prevent 
fluorophore photobleaching. 
viii. The next day, wash the organoids 6x with PBS-T over 6h at 4°C shaking with 
centrifugation at 300 x g for 5 min at 4°C. 
ix. Take up the organoids in 1% low-melting agarose, and transfer them to an 8-well 
chambered cover-glass slide for confocal fluorescence microscopy. 
CRITICAL STEP: Resuspend the organoids in PBS-T and add the equal amount of 




(D)  Transmission electron microscopy of organoids TIMING up to 14d 
i. Release the organoids from Matrigel as described in steps 3| i-iii 
ii. Resuspend the organoids in 7 ml of 2% (w/v) paraformaldehyde and 2.5% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer.  
CAUTION: PFA is toxic and must be handled under a fume hood. 
iii. Fix the organoids for 2h at RT shaking, and wash 2x with 0.1 M phosphate buffer for 
15 min. 
iv. Resuspend the organoids in 500 - 1000 µl 0.1 M phosphate buffer, transfer them to a 
coated 2 ml Eppendorf tube and centrifuge at 300 x g for 5 min at 4°C. 
v. Shortly place the tube in an 80°C heating block before carefully overlaying the 
organoid pellet with 400 µl of 10% agarose. 
vi. Centrifuge at 300 x g for 10 s 
CRITICAL STEP: Place the tube in the centrifuge in the same orientation as before 
to make sure the pellet does not move from its previous position. 
vii. After embedding, post-fix the samples with 1% (v/v) osmium tetroxide, dehydrate in a 
graded series of EtOH, and embed in PolyBed® 812 resin.  
viii. Stain ultrathin sections, 60-80 nm thick, with uranyl acetate and lead citrate, and 




(E)  Harvesting organoids for protein assays  TIMING up to 3h 
It is highly important to reduce the fraction of extracellular proteins from Matrigel within the 
total protein lysate. Therefore, the following procedure was established with the described 
organoid cultures. 
i. Using a 1 ml pipette tip, release organoid-Matrigel lenses from the well, and transfer 
them to an uncoated 15 ml falcon tube to avoid extracellular protein addition in form of 
BSA. 
ii. Wash the wells with 1 ml of PBS to obtain all cells, and add them to the Falcon tube. 
iii. Pipet thoroughly using a 100 µl tip on a 5 ml serological pipet to release the organoids 
from the Matrigel. 
iv. Centrifuge the organoids at 300 x g for 5 min at 4°C, and discard the supernatant, 
including Matrigel and dead cells.  
v. Wash the organoids with ice cold PBS, and centrifuge at 300 x g for 5 min at 4°C. 
CRITICAL STEP: Low temperature of PBS helps to release the organoids from the 
rest of the surrounding Matrigel. 
vi. Resuspend the organoids in 500-1000 µl of ice-cold PBS, transfer to a 2 ml 
Eppendorf tube, and centrifuge at 300 x g for 5 min at 4°C. 
vii. Mix the organoid pellet with 5 ml of Cell Recovery Solution. 
viii. Incubate for 1h at 4°C rotating. 
ix. Centrifuge for 5 min at 300 x g at 4°C, remove the supernatant. 
x. Wash the organoid pellet twice with ice cold PBS. 
xi. Transfer the organoid pellet to an Eppendorf tube using PBS.  
xii. Proceed with preferred method of protein isolation, e.g. using RIPA buffer. In short, 
organoids are resuspended in 100 µl of RIPA buffer containing protease and/or 
phosphatase inhibitors, lysed for 10 min on ice, and centrifuged at 15,000 x g for 10 
min at 4°C. Supernatant can be stored at -20°C after total protein measurement, e.g. 
by Bradford assay. 
 
 
(F)  Organoid viabi l i ty and signaling inhibit ion analysis  TIMING up to 7 d  
The viability of organoids and the effects of inhibitors of specific signaling pathways in 
organoids as well as nephrotoxic substances can easily be analyzed by the Promega 
CellTiter Glo assay.  
i. Release the organoids from Matrigel as described in steps 3| i-iii. 
ii. Resuspend the organoids in 300-500 µl of TrypLE Select cell dissociation enzyme 
solution and incubate for 15-30 min at RT with frequent perturbation by pipetting. 
Check organoid dispersion under the bright-field microscope. 
CRITICAL STEP: Organoid dissociation can easily be monitored by holding the 
falcon tube at an angle in the light path of a bright-field microscope, thereby 
eliminating the need for a hemocytometer for this step.  
CRITICAL STEP: To obtain comparable results, organoids have to be completely 
dissociated to single cells. Depending on the size this requires up to 30 min TrypLE 
dissociation. 
iii. Resuspend 5000 single cells per well in pre-chilled medium and add Matrigel to a 
final concentration of 75% Matrigel. Plate 9 µl cell-Matrigel drops in the middle of the 
well of a pre-heated 96-well plate. 
iv. Invert the plates to prevent cell descent and attachment to the well bottom, while the 
Matrigel containing the cells solidifies for 20 min at 37°C. 
CRITICAL STEP: We recommend marking the position of Matrigel lenses, which 
are not plated exactly in the middle of the well, on the lid to prevent organoid loss 
during medium exchanges. 
CRITICAL STEP: Mark the position of Matrigel drops that attached to the side of 
the well to prevent cell aspiration during medium changes. 
v. Gently add 100 µl of pre-warmed organoid growth medium into each well, and place 
the plate into a CO2 incubator (5% CO2, 37°C). 
vi. Cultivate the organoids with inhibitors for 7 days before performing the assay, 
according to manufacturer’s protocol. In short, resuspend CellTiter Glo Substrate in 
CellTiter Glo Buffer, add the solution to the cell cultures in a 1:2 dilution, and incubate 




Step Problem Possible Reason Solut ion 
2| iv Large tissue pieces 




Increase the digestion 
time, as it is variable 
and depending on 
 tissue size. Perturbate 
the tissue solution 
using a serological 
pipet. 
2| iv Low number of viable 
cells after enzymatic 
digestion 
Digestion time too 
long 
Digestion time is 
variable on tissue. 
Control the digestion 
process regularly and 
stop once most big 
tissue pieces are 
digested. 
2| xi Magnetic columns 
clog during CD45-
depletion. 
Too many cells in the 
solution (maximal 
capacity of the 
column: 2x108 of 
cells) 
Dead cells result in 
cell clumps. 
Dilute cell solution 




Add DNase I at a final 
concentration of 200 
U/ml. 
3| i Organoids die after 
passaging. 
Organoid growth was 
not fully established in 
the culture. Organoids 
were too small or their 
density was too low 
when passaged. 
Grow organoids to at 
least a diameter of 
300-500 µm and 
sufficient density 
before passaging.  
3| ii,  
4| C ix 
Low number of 
organoids after 
harvesting or whole 
mount staining 
Organoids can stick to 
plastic in pipet tips or 
tubes. 
Coat all tubes and 
flush all pipet tips with 
1% BSA in PBS (w/v) 
before e.g. washing 
organoids. 
4| C ix, 
4| D viii 
Mostly fractionated 
organoids visible in 
sections, Whole-
Mount Imaging or 
TEM 
Organoids were too 
large when harvested. 
Handling of organoids 
was not careful 
enough. 
Harvest organoids 
when they are at a 
diameter of 300-500 
µm to prevent rupture. 
During organoid 
preparation avoid 




Steps 1-3, establishing and passaging human tumor kidney organoids: variable up to 2 
weeks 




Our protocol describes an efficient method for cultivating organoids of human clear cell renal 
cell carcinoma (ccRCC). Organoids are 3D structures grown from stem cells, which 
differentiate into organ-specific cell types that self-organize through cell sorting and spatially 
restricted lineage commitment4. Renal cell carcinoma organoids described in previous 
publications showed inferior organoid formation efficiencies, could only be maintained for few 
passages, and were not fully characterized. Here we established organoids from kidney 
tumor biopsies that recapitulate their tissues of origin ex vivo and could be passaged and 
cultivated as a promising patient-specific pre-clinical in vitro model.  
Following this protocol, rounding of cells and formation of small organoids can be detected 
within 2-3 d after seeding (Fig. 1a). Tumor-derived cells showed an organoid formation 
efficiency of 0,084%, which could be increased to 0,191% by previous sorting for cancer 
stem cells5. Generally, heterogeneity could be observed between cultures of different 
patients, however cystic structures were predominantly formed (Fig. 1a). Tumor organoids 
retained intra- as well as inter-tumor heterogeneity containing cystic as well as solid and 
tubular structures (Fig. 1b), thereby making them an excellent pre-clinical model for 
personalized medicine15. 
To confirm the cellular identity of the organoids, immunofluorescence can be performed: 
tumor organoids should express the renal carcinoma marker carbonic anhydrase IX as well 
as the epithelial differentiation marker E-cadherin. As the tumor organoids established in this 
protocol recapitulate the proximal tubule as the putative cell-of-origin of ccRCC, organoids 
should also stain positively for lotus tetragonolobus, LTL (Fig. 2a,b). 
The complexity of organoid cultures can further be analyzed by transmission electron 
microscopy. Tumor organoids are polarized and show high numbers of cell interactions, 
including tight and adherens junctions as well as desmosomes that seal the inter-cellular 
space from the lumen. Organoids produce brush border structures on the luminal side, 
coinciding with positive LTL staining, and present ccRCC characteristics including lipid 
droplets and glycogen accumulation (Fig. 2c). 
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Fig. 1: Morphology of ccRCC organoids 
(a) Representative bright-field images of an organoid growing from a single cell over 10 days. 
(scale bar, 100 µm). (b) Left: Bright-field pictures of representative cystic, solid and tubular 
organoid cultures. Right: HE stainings of representative organoids (scale bars, 250 µm) 
 
Fig. 2: Functional characterization of ccRCC organoids 
(a) Immunofluorescence after 7 days of culture for DAPI, Carbonic Anhydrase IX (CA9), E-
Cadherin (ECAD) and LTL (scale bars, 50 µm). (b) Whole-mount images of DAPI (blue), CA9 
(green), ECAD (orange) and LTL (red). Pictures are 15 µm apart (scale bar, 100 µm). (c) 
Transmission electron microscopy of representative organoid cultures (see scale bars for 
sizes): L, luminal side; D, desmosomes; AJ, adherens junctions; arrowheads, tight junctions; 
arrows, lipid droplets; asterisks, glycogen deposits (Data previously published5).  
 
 
